Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis

In this analysis, we examined counts of individuals with type 2 diabetes initiating canagliflozin or comparators in the Sentinel Distributed Database (SDD), and captured available follow-up time, days supplied, and renal cell carcinoma events among these individuals.

We conducted this analysis in two separate runs with different study periods. The first run includes data from March 29, 2013 to October 31, 2021. The second run includes data from October 1, 2015 to October 31, 2021. We distributed this request to seven Sentinel Data Partners on June 10, 2022.